

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L5	2	5707964.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:21			0
2	BRS	L6	2	5989545.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:22			0
3	BRS	L7	2	wo-9009799-\$.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:24			0
4	BRS	L8	496	botulinum adj toxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:32			0
5	BRS	L9	19	tetani adj toxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:31			0
6	BRS	L10	10	butyricum adj toxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:32			0
7	BRS	L11	165	gnrh adj receptor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:47			0
8	BRS	L12	88	clostridial adj toxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:33			0
9	BRS	L13	2	(8 or 9 or 10 or 12) same 11	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:49			0
10	BRS	L14	1239	gnrh	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:47			0
11	BRS	L15	0	(8 or 9 or 10 or 12) same 14 same conjugate	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:48			0
12	BRS	L16	2	(8 or 9 or 10 or 12) same 14	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:48			0
13	BRS	L17	436	gonadotropin same disorder	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:49			0
14	BRS	L18	0	(8 or 9 or 10 or 12) same 17 same conjugate	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:49			0
15	BRS	L19	0	(8 or 9 or 10 or 12) same 17	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:52			0
16	BRS	L20	59	donovan adj stephen.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:53			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
17	BRS	L21	1	20 and 11	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 15:53			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error
1	BRS	L1	2	((botulinum adj toxin) or (tetani adj toxin) or (butyricum adj toxin) or (clostridial adj toxin)) same (gnrh)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 16:06		0	
2	BRS	L2	119472	cancer or endometriosis or (precocious adj puberty)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 16:07		0	
3	BRS	L3	1	1 same 2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/27 16:07		0	

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 27 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

15:58:14 ON 27 MAR 2003

L1 18481 S BOTULINUM TOXIN
L2 486 S CLOSTRIDIAL TOXIN
L3 402 S TETANI TOXIN
L4 10 S BUTYRICUM TOXIN
L5 19266 S L1 OR L2 OR L3 OR L4
L6 50493 S GNRH
L7 0 S L6 (P) L5 (P) CONJUGATE
L8 0 S L5 (P) L6
L9 2230 S GONADOTROPHIN (P) (DISORDER OR DISEASE)
L10 2 S L9 (P) L5
L11 2 DUPLICATE REMOVE L10 (0 DUPLICATES REMOVED)
L12 529912 S (BREAST CANCER) OR (PROSTATE CANCER) OR
(PANCREATIC CANCER) O
L13 1 S L12 (P) L5

=> log y

FILE 'HOME' ENTERED AT 15:57:48 ON 27 MAR 2003

=> file medline caplus biosis embase scisearch agricola

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 15:58:14 ON 27 MAR 2003

FILE 'CAPLUS' ENTERED AT 15:58:14 ON 27 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:58:14 ON 27 MAR 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 15:58:14 ON 27 MAR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:58:14 ON 27 MAR 2003

COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 15:58:14 ON 27 MAR 2003

=> s botulinum toxin

L1 18481 BOTULINUM TOXIN

=> s clostridial toxin

L2 486 CLOSTRIDIAL TOXIN

=> s tetani toxin

L3 402 TETANI TOXIN

=> s butyricum toxin

L4 10 BUTYRICUM TOXIN

=> s l1 or l2 or l3 or l4

L5 19266 L1 OR L2 OR L3 OR L4

=> s gnrh

L6 50493 GNRH

=> s l6 (p) l5 (p) conjugate

L7 0 L6 (P) L5 (P) CONJUGATE

=> s l5 (p) l6

L8 0 L5 (P) L6

=> s gonadotrophin (p) (disorder or disease)

4 FILES SEARCHED...

L9 2230 GONADOTROPHIN (P) (DISORDER OR DISEASE)

=> s l9 (p) l5

L10 2 L9 (P) L5

=> duplicate remove l10

PROCESSING COMPLETED FOR L10

L11 2 DUPLICATE REMOVE L10 (0 DUPLICATES REMOVED)

=> d l11 1-2 ibib abs

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:736127 CAPLUS

DOCUMENT NUMBER: 137:257666

TITLE: Compositions and methods using a neurotoxin for treating gonadotrophin-related illnesses

INVENTOR(S): Donovan, Stephen

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 97 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

CODEN: PTXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074327	A2	20020926	WO 2002-US7379	20020311
WO 2002074327	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002177545 A1 20021128 US 2001-810601 20010315

PRIORITY APPLN. INFO.: US 2001-810601 A 20010315

US 2000-692811 A2 20001020

OTHER SOURCE(S): MARPAT 137:257666

AB The invention discloses an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine ***disorders***, e.g. ***gonadotrophin*** -related illnesses. Preferably, the agent comprises at least a portion of a ***botulinum*** ***toxin***.

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:907158 CAPLUS

DOCUMENT NUMBER: 138:665

TITLE: Compositions and methods for treating gonadotrophin related illnesses

INVENTOR(S): Donovan, Stephen

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U. S. Ser. No. 692,811.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002177545	A1	20021128	US 2001-810601	20010315
WO 2002074327	A2	20020926	WO 2002-US7379	20020311
WO 2002074327	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-692811 A2 20001020

US 2001-810601 A 20010315

OTHER SOURCE(S): MARPAT 138:665

AB The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine ***disorders***, for example ***gonadotrophin*** -related illnesses. Preferably, the agent comprises at least a portion of a ***botulinum*** ***toxin***.

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 27 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOS EMBASE, SCISEARCH, AGRICOLA' INDEXED AT
15:58:14 ON 27 MAR 2003

L1 18481 S BOTULINUM TOXIN
L2 486 S CLOSTRIDIAL TOXIN
L3 402 S TETANI TOXIN
L4 10 S BUTYRICUM TOXIN
L5 19266 S L1 OR L2 OR L3 OR L4
L6 50493 S GNRH
L7 0 S L6 (P) L5 (P) CONJUGATE
L8 0 S L5 (P) L6
L9 2230 S GONADOTROPHIN (P) (DISORDER OR DISEASE)
L10 2 S L9 (P) L5
L11 2 DUPLICATE REMOVE L10 (0 DUPLICATES REMOVED)

=> s (breast cancer) or (prostate cancer) or (pancreatic cancer) or (endometriosis) or (endometria
5 FILES SEARCHED...

L12 529912 (BREAST CANCER) OR (PROSTATE CANCER) OR (PANCREATIC CANCER) OR
(ENDOMETRIOSIS) OR (ENDOMETRIAL CANCER) OR (PRECOCIOUS PUBERTY)

=> s l12 (p) 15

L13 1 L12 (P) L5

=> d l13 1 ibib abs

L13 ANSWER 1 OF 1 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 97196749 EMBASE
DOCUMENT NUMBER: 1997196749
TITLE: [Endoscopic ultrasonography of the alimentary system].
ULTRASONOGRAFIA ENDOSKOPOWA UKLADU POKARMOWEGO.
AUTHOR: Kohut M.
CORPORATE SOURCE: M. Kohut, Klinika Gastroenterologii, Slaska Akademia
Medyczna, ul. Medykow 14, 40-752 Katowice, Poland
SOURCE: Gastroenterologia Polska, (1997) 4/2 (181-190).
Refs: 36
ISSN: 1232-9886 CODEN: GASPF4
COUNTRY: Poland
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 014 Radiology
048 Gastroenterology
LANGUAGE: Polish
SUMMARY LANGUAGE: Polish; English

AB Endoscopic ultrasound (EUS) is one of the youngest endoscopic viewing methods. The author described the technical aspects of the method - the equipment and practical problems of the examination of different parts of the digestive tract. Established and experimental indications for EUS are described. The established indications for EUS include: - locoregional staging of neoplastic diseases of esophagus, stomach, pancreas, distal part of the biliary tract, - investigation of submucosal abnormalities (including differentiation of their intramural or extrinsic origin), - evaluation of large gastric folds, - searching for small (less than 2 cm) focal changes in the pancreas (***pancreatic*** ***cancer*** , pancreatic endocrine tumors). The list of the experimental indications includes: - in the esophagus - the diagnostics of carcinoma in Barret's esophagus, identification of paraesophageal varices, evaluation of esophageal varices after their sclerotherapy or banding, - in the stomach - the assessment of ulcer healing, evaluation of bleeding gastric ulcer, - in the pancreas - the estimation of chronic pancreatitis, assessment of pancreatic cysts before their endoscopic evaluation (gastro- and duodenocystostomia), - in the biliary tree- cholecysto- and choledocholithiasis, - in the colon and rectum - locoregional staging of colorectal cancer, evaluation of the wall in colitis ulcerosa and Crohn's disease (fistulae and abscesses), the function of rectal sphincters in different disorders. In the description of the experimental indications for EUS it is emphasized that some of them can rapidly become established (e.g. the diagnostics of choledocholithiasis). Another group of indications is the so called 'interventional EUS' (or 'operative EUS') and includes: - invasive diagnostics: needle aspiration of tumors suspected of malignancy and lymph nodes under the direct visual control of EUS, thoraco- and paracentesis under EUS guidance, injections of contrast medium into the biliary tree and Wirsung duct under EUS visual control (performed if ERCP is impossible) and Doppler scanning of vascular

structures after hemostatic endoscopic procedures, - therapeutic procedures: transgastric celiac plexus block, EUS-assisted pancreatic pseudocyst drainage, EUS-assisted endoscopic resection of mucosal and submucosal masses, EUS-guided ***botulinum*** ***toxin*** injection in achalasia primaria. Estimating the contraindications and complications of EUS the author judges the method to be safe. Being difficult and requiring expensive equipment, EUS is recommended to be used in reference centres. In such places EUS can be learned and taught properly as well as completely utilized.

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 27 MAR 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 15:58:14 ON 27 MAR 2003

```
L1      18481 S BOTULINUM TOXIN
L2      486 S CLOSTRIDIAL TOXIN
L3      402 S TETANI TOXIN
L4      10 S BUTYRICUM TOXIN
L5      19266 S L1 OR L2 OR L3 OR L4
L6      50493 S GNRH
L7      0 S L6 (P) L5 (P) CONJUGATE
L8      0 S L5 (P) L6
L9      2230 S GONADOTROPHIN (P) (DISORDER OR DISEASE)
L10     2 S L9 (P) L5
L11     2 DUPLICATE REMOVE L10 (0 DUPLICATES REMOVED)
L12     529912 S (BREAST CANCER) OR (PROSTATE CANCER) OR (PANCREATIC CANCER) O
L13     1 S L12 (P) L5
```

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	60.40	60.61
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 16:05:45 ON 27 MAR 2003